Author Archives: David Melamed, PhD

AC Immune Partners With WuXi to Speed Development of TDP-43 Antibody

AC Immune and WuXi Biologics have announced a partnership to advance the development of an investigational antibody treatment that targets the protein TAR binding DNA protein 43 (TDP-43) for treating certain central nervous system (CNS) conditions, including amyotrophic lateral sclerosis (ALS). Having identified and developed the anti-TDP-43…

Japan Grants Patent to Brainstorm Covering Technique for NurOwn

The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates the company’s cell-based therapy NurOwn from mesenchymal stem cells (MSCs). Through this technique, researchers can harness MSCs directly from a patient and mature them into cells that produce…

PrimeC Shows Potential to Slow ALS Progression, Interim Data Reveal

PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and shows potential to slow disease progression and lung function decline, according to interim results from a Phase 2a clinical trial. Given these results, developer NeuroSense Therapeutics will continue investigating PrimeC with additional analysis…